Tevogen Bio

📰 globenewswire.com/news-release/2… 🔹Lead investor confirmed his intention to maintain his current shareholdings. 🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive. 🔹Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers. 🔹Company prioritizing long-term stock-based incentive program aligned with company milestones. 🔹Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders. 🔹Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue. 🔹Company exploring avenues to better reflect value of assets. $TVGN

“This event embodies Vision 2030’s commitment to building an advanced health ecosystem grounded in scientific research and international partnerships, to develop innovative solutions that serve our citizens, the region and contribute to humanity worldwide.” — H.E. Fahad bin Abdulrahman Aljalajel, Minister of Health, Kingdom of Saudi Arabia @FahadAlJalajel @SaudiMOH This will save lives. A timely step forward for humanity. —Founder & CEO, @TevogenBio @TevogenAI $TVGN #Biotech Image courtesy: #BIOMiddleEast